2024-05-29 13:43:45 ET
Summary
- Merck stock is still a buy despite near-record stock prices.
- Thanks to its growth outlook, its current valuation is still far below the Graham P/E, leaving a wide margin of safety.
- Its well-balanced business model, top-grossing Keytruda franchise, and superb financial strength further skew the return/risk profile.
MRK stock: Still a Buy
We last covered Merck ( MRK ) back in July 2022 with a bullish thesis (as you can see from the chart below). At that time, the stock was trading around $75 per share at about 12.5x FWD P/E. And the bullish thesis was pretty obvious to us (with our key points quoted below)....
Read the full article on Seeking Alpha
For further details see:
Merck Stock: Still Discounted To Graham P/E